The Pentagon will add yearly testosterone tests to routine health exams for active‑duty personnel 30 years and older, with optional hormone therapy for diagnosed cases.
The Department of Defense will add yearly testosterone tests to routine health exams for active‑duty personnel 30 years and older. The policy, announced by Defense Secretary Pete Hegseth on July 15, 2026, applies to all branches of the U.S. military and includes optional testosterone replacement therapy for diagnosed cases [1].
The announcement was made during a press briefing at the Pentagon on Wednesday, July 15, 2026. The directive specifies that the screening will be incorporated into existing annual medical assessments for active‑duty service members who have reached their 30th birthday [1]. The program will be rolled out across all U.S. military installations and will be administered by the Military Health System [4].
Defense Secretary Pete Hegseth led the rollout, citing the need to preserve the “biological foundation” required for combat readiness [1]. The Department of Defense, through the Pentagon’s Health Affairs office, will oversee the mandatory testing, while the Defense Health Agency will manage the clinical protocols [3][4]. Service members who receive a diagnosis of low testosterone will be offered optional testosterone replacement therapy (TRT) under existing medical guidelines [1].
Program Details and Implementation
The screening will use a standard serum testosterone assay performed during the annual physical exam. Results below the medically established threshold will be flagged for follow‑up evaluation [1]. Participation is compulsory for all active‑duty personnel aged 30 and older, regardless of gender or rank [2][4]. The Defense Health Agency has allocated additional laboratory resources to accommodate the increased testing volume and has issued training directives to medical personnel at military treatment facilities [3].
Optional TRT will be prescribed only after a confirmatory diagnosis, a review by a qualified military physician, and compliance with existing contraindication criteria [1][3]. The therapy will be administered through the same channels that deliver other prescription medications to service members, ensuring continuity of care and monitoring for adverse effects [4]. The program’s budgetary impact is being funded through the FY 2027 Defense Health Program allocation, with an estimated $45 million earmarked for laboratory costs and physician training [2].
Defense Secretary Pete Hegseth led the rollout, citing the need to preserve the “biological foundation” required for combat readiness [1].
Implications for Recruitment and Health Policy
Pentagon Announces Mandatory Annual Testosterone Screening for Service Members Aged 30+
The initiative aligns with broader Department of Defense efforts to standardize preventive health measures across the force [3]. By addressing testosterone deficiency, the military aims to reduce fatigue, musculoskeletal injuries, and other health issues linked to low hormone levels, potentially extending the service life of older personnel [1]. Recruitment officers have been briefed on the new health requirement, and recruitment messaging will now reference the program as part of the service’s commitment to soldier wellness [4].
A University of California survey reports that nine‑in‑ten undergraduate students regularly use generative AI tools for coursework, highlighting access gaps and the need for educator…
Policy analysts note that the screening could influence enlistment decisions for individuals approaching the age‑30 threshold, as the requirement adds an additional health evaluation step [2]. However, the Department has emphasized that the program does not affect eligibility for enlistment; it applies only after a service member reaches the specified age [3]. The initiative also sets a precedent for other preventive health screenings, such as cardiovascular and mental‑health assessments, that may be expanded in future directives [4].
Impact on Service Members
Active‑duty personnel 30 years and older will receive the testosterone test during their scheduled annual physical, typically conducted at a base medical clinic [1]. Positive results will trigger a referral to a military endocrinologist or primary care provider for further assessment [3]. Service members who opt for TRT will be monitored quarterly for hormone levels, side effects, and performance metrics, as outlined in the Defense Health Agency’s clinical guidelines [4].
The program is expected to improve overall readiness by identifying and treating a condition that can affect energy, mood, and physical performance [1]. For service members, the mandatory nature of the test eliminates the need for self‑referral, ensuring uniform access to diagnosis and treatment [2]. The initiative also provides a data set for longitudinal studies on hormone health within the armed forces, potentially informing future medical policy [3].
Key Facts
What: The U.S. military will conduct mandatory annual testosterone screenings for active‑duty personnel aged 30 and older.
The initiative also sets a precedent for other preventive health screenings, such as cardiovascular and mental‑health assessments, that may be expanded in future directives [4].
When: Announcement made July 15, 2026; implementation to begin later in 2026.
Impact: Service members will receive testing during routine health exams, with optional hormone therapy for diagnosed cases, affecting health management and recruitment processes.
The United States announced a 50 % tariff on $20 billion of Canadian imports, targeting cars, alcohol, and dairy, effective 30 days after July 20, 2026.
NewsNews
